The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour ...

Researchers from Australia and Germany have for the first time cured patients suffering from toxic epidermal necrolysis (TEN) ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure ...

SYDNEY: Researchers from Australia and Germany have for the first time cured patients suffering from toxic epidermal ...

Dizal seeks US FDA approval for sunvozertinib to treat relapsed or refractory NSCLC with EGFR Exon 20 insertion mutations: Shanghai, China Saturday, November 9, 2024, 17:00 Hrs [I ...

Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -- Phase 1 ...

Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of ...

Basal cell carcinoma (BCC) is a heterogeneous malignant neoplasm and can cause great morbidity as most occur in highly visible areas ...

Transcription activation of genes by estrogens is driven by enhancers, which are often located within the same Topologically Associating Domain (TAD) as non-targeted promoters. We investigated how ...

More than paying lip service, the cells may offer new opportunities to research and treat various lip conditions ...

Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in ...